Datwin, Baby Girl .

HRN: 21-39-78  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/26/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/26/2022
07/03/2022
IV
30mg
Q24h
Potentially Septic Newborn
Waiting Final Action 

Indication:  ProphylaxisEmpiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: